Overall impact
C (53)

Commentary

AtriCure is an average overall performer. With a 'C' rating of 52.8 for overall impact (47th percentile compared to all companies), AtriCure ranks 84th out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 80 others, and ahead of Orthopediatrics, Integra Lifesciences, TransMedics Group and 16 others. On top material causes for AtriCure's industry (Healthcare Equipment), AtriCure performs well in Child and Maternal Health (81.7 score) and performs poorly in Disaster Readiness and Effective Aid (34.4 score), Humane Treatment of Animals (18.9) and Access to Affordable Healthcare (33.2).
Impact
Cause ATRC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
1,350
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Oh, United States
Share classes
ATRC
Description
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency product; multifunctional pens and linear ablation devices, single-use disposable RF products for the treatment of cardiac arrhythmias; and the cryoICE Cryoablation System, which enables the user to make linear ablations of varied lengths. Additionally, AtriCure provides EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also offers the cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercostal peripheral nerves in the ribcage. The company features the AtriClip System, an implantable device coupled to a single-use disposable applier; the LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannulas to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Material causes
Ethos considers the following causes material for AtriCure, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.